Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Allowance against trade accounts receivable by Year
Allowance against trade accounts receivable — Chargebacks, discounts & returns ($M) ($M)
Pfizer Allowance against trade accounts receivable: $1,803M in FY2025, up 10.8% from a year earlier.
Latest, FY2025
1,803
Period ended Dec 31, 2025
Change on a year earlier
+10.8%
1,627 in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Note 17 — Revenue Deductions & Rebate Accruals.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Allowance against trade accounts receivable — Chargebacks, discounts & returns ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,803 | +10.8% | Form 10-Q (filed 2026-08-04) ↗ |
| FY2024 | Dec 31, 2024 | 1,627 | -8.1% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 1,770 | +47.5% | Form 10-K (filed 2025-02-27) ↗ |
| FY2022 | Dec 31, 2022 | 1,200 | +11.4% | Form 10-K (filed 2024-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 1,077 | +25.1% | Form 10-K (filed 2023-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 861 | +4.6% | Form 10-K (filed 2022-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 823 | – | Form 10-K (filed 2021-02-25) ↗ |
Cite this data
StockData. (2026). Pfizer Allowance against trade accounts receivable ($M), annual FY2019–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/gtn-ar-reserve
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.